Introduction and objective:
Gastric cancer (GC) is one of the biggest healthcare problems worldwide. Despite the fact that the incidence of this cancer has decreased recently, GC is in the fifth place of causes of morbidity, and in the second place of causes of mortality. Therefore, some countries such as Japan and South Korea have established and developed screening methods to detect GC as early as possible and to begin early treatment.

Materials and method:
Review methods were based on articles available in the following databases: PubMed, UpToDate, among others.

Brief description of the state of knowledge:
There are many types of screening methods, such as, markers of atrophy-serum-pepsinogen test and low serum gastrin-17 concentration, barium photofluorography of mucosa, or endoscopy. Upper gastrointestinal endoscopy has the highest detection rate in high-incidence areas, compared to other screening methods, because upper endoscopy makes it possible to highlight changes such as flat and non-ulcerative lesions, which are usually invisible in barium examination. An alternative to screening is the massive eradication of Helicobacter pylori. Some countries occasionally recommend genetic testing and prophylactic gastrectomy.

Despite the high incidence of GC in Asian countries, there is still a lack of data on the cost-effectiveness of mass screening for GC. The main factor influencing the profitability of screening tests for GC is the cost of upper gastrointestinal endoscopy. Moreover, the value and usefulness of the GC screening programme remains controversial in many countries

Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari R. Gastric cancer prevention strategies: A global perspective. Journal of Gastroenterology and Hepatology. 2020; 35(9): 1495–1502. doi: 10.1111/jgh.15037.
Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F. Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention. Cancer Epidemiology, Biomarkers&Prevention. 2014; 23(5): 700–713. doi: 10.1158/1055-9965.EPI-13-1057.
Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Annals of Internal Medicine. 2009; 151(2): 121–128. doi: 10.7326/0003-4819-151-2-200907210-00009.
Sano, T. Gastric cancer: Asia and the world. Gastric Cancer. 2017; 20: 1–2. doi: 10.1007/s10120-017-0694-9.
Leung WK, Wu M, Kakugawa Y, Kim JJ, Yeoh K, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. The Lancet Oncology. 2008; 9(3): 279–87. doi: 10.1016/S1470-2045(08)70072-X.
Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World Journal of Gastroenterology. 2014; 20(38): 13842–13862. doi: 10.3748/wjg.v20.i38.13842.
Hamashima C. Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Japanese Journal of Clinical Oncology. 2018; 48(7): 673–683. doi: 10.1093/jjco/hyy077.
Chen, Xian-Zhe, Huang, Cheng-Zhi, Hu, Wei-Xian, Liu, Ying, Yao, Xue-Qing. Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations. Chinese Medical Journal. 2018; 131(10): 1232–1239. doi: 10.4103/0366-6999.231512.
Yu G, Wang GX, Wang HG, Mo FF, Tang BB. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. Neoplasma. 2019; 66(4): 637–640. doi: 10.4149/neo_2018_180825N647.
Pérez-Mendoza A,. Zárate-Guzmán ÁM, Galvis García ES, Sobrino Cossío S, Djamus Birch J. Aplicación de la endoscopia sistemática alfanumérica codificada más cromoendoscopia para la detección de lesiones precancerosas gástricas y cáncer gástrico temprano en sujetos con riesgo promedio de cáncer gástricoSystematic alphanumeric-coded endoscopy versus chromoendoscopy for the detection of precancerous gastric lesions and early gastric cancer in subjects at average risk for gastric cancer. Revista de Gastroenterología de México. 2018; 83(2): 117–124. doi: 10.1016/j.rgmx.2017.06.004.
Yoshida N, Doyama H, Yano T, et al. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging. Gut. 2021; 70: 67–75. doi: 10.1136/gutjnl-2019-319631.
Chan Park, et al. Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer. Journal of Gastroenterology and Hepatology. 2019; 34(1): 84–91. doi: 10.1111/jgh.14471.
Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet. 1996; 348(9021): 150–154. doi: 10.1016/s0140-6736(96)01501-2.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020; 69(12): 2093–2112. doi: 10.1136/gutjnl-2020-322368.
Zhang X, Li M, Chen S, Hu J, Guo Q, Liu R, Zheng H, Jin Z, Yuan Y, Xi Y, Hua B. Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review. Gastroenterology. 2018; 155(2): 347–354. doi: 10.1053/j.gastro.2018.04.026.
Saumoy M, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. Gastroenterology. 2018; 155(3): 648–660. doi: 10.1053/j.gastro.2018.05.026.
Journals System - logo
Scroll to top